Autopsy report · NCT04131192
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Cause of deathOther
“Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 1 year 10 months before it stopped.
- 13 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Pancreatic Cancer
- Interventions
- Z650; Gemcitabine
- Participants
- 13
- Sites
- 2
- Countries
- China
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.